We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Radiotherapy can be a Cofactor in the Development and Severity of Lapatinib-Capecitabine-Related Skin Rash.
- Authors
DUMAN, Nilay; DEMIR, Meryem; ON, Sercan; OZSARAN, Zeynep
- Abstract
Skin rash induced by concurrent radiotherapy during lapatinib-capecitabine (LC) treatment has been rarely reported. We aim to draw attention to the potential of radiotherapy to act as a cofactor in the development of LC-related skin rash. Herein, we report a case with a drug-related skin rash triggered by radiotherapy during LC treatment. A 31-year-old woman with inflammatory metastatic breast cancer presented with a skin rash during LC treatment combined with radiotherapy. She was started on LC treatment, and palliative whole cranial radiotherapy was applied 3 days later. Three days after the radiotherapy, acneiform lesions started from the scalp and a maculopapular rash developed on the trunk and extremities. LC treatment was interrupted and skin lesions regressed rapidly with topical dermatological care, oral H1-antihistamine, and short-term oral steroid treatment. Although LC treatment was restarted alone in the follow-up, no recurrence was observed. Radiotherapy may be a cofactor in the development and severity of skin toxicity during LC treatment. There is a need to elucidate whether the immunological mechanisms of skin eruptions occurring during concomitant chemoradiotherapy are due to the radiosensitizing effects of biological agents or exacerbation by radiotherapy.
- Subjects
CUTANEOUS therapeutics; RADIOTHERAPY; ACNEIFORM eruptions; ANTINEOPLASTIC agents; BREAST tumors; EXANTHEMA; EXTREMITIES (Anatomy); TERMINATION of treatment; SKIN care; ANTIHISTAMINES; CHEST (Anatomy); DRUG eruptions; DISEASE risk factors
- Publication
Asthma Allergy Immunology / Astim Allerji Immunoloji, 2024, Vol 22, Issue 1, p82
- ISSN
1308-9234
- Publication type
Article
- DOI
10.21911/aai.247